ModernMedicine Resource Center More Topics

DME Resource Center

FDA approves Iluvien for long-term treatment of DME; Alimera reactsThe FDA has approved Alimera Sciences’ fluocinolone acetonide intravitreal implant (Iluvien) for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP.
Iluvien for chronic DME approved for marketing in Denmark, NorwayThe Danish Health and Medicines Authority, along with the Norwegian Medicines Evaluation Board, have granted marketing authorization to Alimera Sciences’ Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema (DME) in their respective countries.
RIDE, RISE phase III results favorable for DME treatment
RIDE, RISE phase III results favorable for DME treatmentThe open-label extension RIDE and RISE phase III studies of ranibizumab (Lucentis, Genentech) indicated that the beneficial results of the drug for treating diabetic macular edema were maintained over the long-term with less than monthly follow-up or injection treatment.
ThromboGenics to expand VMA, DME researchThromboGenics has taken steps to expand its research of treatments for vitreomacular adhesion (VMA) and diabetic macular edema (DME).
Exploring future treatments of diabetic macular edema
Exploring future treatments of diabetic macular edemaThe future of treatment for diabetic macular edema is likely to include a wider range of treatment options, improved efficacy, and the possibility of disease prevention.
Navilas laser chosen for DME studyOD-OS has announced that its Navilas laser has been selected for a new study to evaluate the efficacy and stability of laser plus anti-vascular endothelial growth factor for the treatment of patients with diabetic macular edema (DME).